CNC, University of Coimbra, PT
Ricardo Marques obtained his BSc in Biochemistry at the University of Beira Interior in 2007. Afterwards, he undertook an advanced MSc in Molecular and Cellular Biology at the University of Coimbra. Awarded with a PhD fellowship from the Science and Technology Foundation (FCT) in 2009, Ricardo demonstrated during the PhD the protective role of regucalcin protein in breast cancer initiation and development by controlling several biomolecular mechanisms as cell cycle, proliferation and apoptosis. He also collaborated on the assessment of regucalcin in prostate carcinogenesis and hormonal effects on its expression. To further engage his career in the cancer field, he initiated in June 2016 a postdoctoral position at Dr. Leonie Young lab Endocrine Oncology Research Group at the Royal College of Surgeons in Ireland (RCSI). Focusing on the disclosure of breast cancer molecular mechanisms regarding endocrine therapies resistance, Ricardo contributed to the development of a project, in collaboration with Pfizer, for a novel biotherapeutic treatment of ER-positive primary and meta breast cancer. Since the end of 2017, Ricardo joined Dr. Paulo Oliveira group at the MitoXT- Mitochondrial Toxicology and Experimental Therapeutics laboratory at the Center for Neuroscience and Cell Biology (CNC) in University of Coimbra. Currently, Ricardo project is related to how a specific protein may affect cancer stem cells metabolic remodelling and mitochondria of those cells. His is also interested in understanding how cancer cells adapt their metabolism to the environment, evade therapy and to test new therapeutic strategies associated with the metabolic shift.